Icon

Astepro - (EQ 0.1876/0.125 mg; Base/Spray)

Azelastine Hydrochloride Meda pharma
EQ 0.1876/0.125 mg; Base/Spray
Less Than $1000 mn
Less Than 5
More Than 5
Less Than 5
None
More Than 5
More Than 5
Indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older.
Yes
****** *** ******* *** ****** **** **** ****** '*** (**** **, ****) *** ** ****** **** *** ******* *****. ***** ****** *** ****** (** ********** ****** '***- *** **, ****), ***** & ****** **** ***** **** ** *** ************ ********* ** ****. **** ****** *** ******* ********* ***** ***** ****, *** **** *** *** ********* ** *** ** ******, **** ***** ********* **** *** ****** ** ******** ******* ****** ***** *** ** ****** *** ******* **** ********* ******** *** ******* ******** *** ******* . *** ********** ** ********* **** *** *** ********* ***** *** ***** ** ********* *** *** *****.
Astepro Patent 1 Patent 2 Patent 3
******* ******* ******* *******
****** ******* ******* *******
***** ****** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** **** **,**** ******* ******** ******** ** *** *, ****
****** *** \ *** **** **,**** ******* ******** ******** ** *** *, ****
***** ****** ** \ ** *** **,**** ******* **** ****** **** ********
  1. *** **, **** : ****** *** ******* ******** **** ***** ***** **** ** **** ****** '***- **** **, ****.
  2. *** **, **** : **** **** ****** *** ******* ** ******** ***** ** *** ******.
  3. **** **, **** : ****** ******** **** ***** *** **** ** **** ****** '***.
  4. **** **, **** : **** **** ****** ** ******** ***** ** *** ******.
  5. *** **, **** : ****** *** ***** ******** *** *** *** ****** *** *******.
  6. *** **, **** : ********** *** ********* **** ****** ***** ****** ****** **** *** **** ***** ******** ****** '*** *** **** ** **** *** ****** *** ******* **** ****** '*** ** ****** *******.
  7. *** *, **** : ******* ******** ******** *** ******** *** *******.
  8. *** **, **** : ********** *** ********* **** ******* ***** ******* ****** **** *** **** ***** ******** ****** '*** *** **** ** **** *** ****** *** ******* **** ****** '*** ** ****** *******.
  9. *** **, **** : **** ***** * **** ******* ****** & ****** ********** ** *** *** ********* ********** ***** **** ** **** ******* '***- **** **, ****, '***-*** **, ****.
  10. *** *, **** : ***** *** **-**** ******** ********* **** ** ******* '***- **** **, ****, '***-*** **, ****.
  11. *** **, **** : **** **** ***** ** ** ** ********
  12. *** *, **** : ********** *** ********* **** *****, ****** & ****** ***** *** ***** ** ********* *** *** *****.
  13. *** **, **** : **** ***** * **** ******* ********* ** *** *******.
  14. *** *, **** : ********** ********* **** ********* ** *** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.